Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Anastrozole and Rapamycin Interaction: Monitor | Peptide Database

Compound Profiles Anastrozole Aromatase Inhibitor | Estrogen Management Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Rapamycin

mTOR Inhibitor | Longevity & Immunosuppression

Rapamycin exerts its effects by binding to the intracellular protein FKBP12, forming a complex that directly and specifically inhibits mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 is a master nutrient-sensing kinase that integrates signals from growth factors, amino acids, energy status, and stress to regulate cell growth, proliferation, and metabolism.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Anastrozole with Rapamycin?

Yes, but with caution. Both Anastrozole and Rapamycin negatively affect lipid profiles. Combined use may significantly worsen HDL/LDL ratios. Include lipid support and get bloodwork mid-cycle. Regular monitoring is advised.

Is Anastrozole and Rapamycin safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between Anastrozole and Rapamycin?

Both Anastrozole and Rapamycin negatively affect lipid profiles. Combined use may significantly worsen HDL/LDL ratios. Include lipid support and get bloodwork mid-cycle. This assessment has 55% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anastrozole and Rapamycin?

Anastrozole has a half-life of ~40-50 hours and Rapamycin has a half-life of ~62 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss. ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss. Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%). 91% achieved near-normal blood sugar levels versus 42% with placebo. ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%. Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.

Source: peptide-db.com ↗

Research Indications

FDA-approved for postmenopausal women with osteoporosis at high risk for fracture or who have failed other therapies. FDA-approved for men with osteoporosis at high risk for fracture or intolerant to other treatments. Phase III trials demonstrated substantial reduction in vertebral and nonvertebral fractures. ACTIVExtend trial showed benefits of abaloparatide followed by alendronate for maintained bone protection.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Subcutaneous injection is the primary administration route. Best administered on an empty stomach for optimal GH release. Multiple daily doses recommended to maintain elevated GH levels. GH optimization 100-150 mcg 2-3x daily SubQ Enhanced results 200-300 mcg With GHRH (synergy) 100 mcg each SubQ (combined) Pre-sleep protocol 100-200 mcg Before bed

Source: peptide-db.com ↗
Side effects

Common Side Effects

Hepatic stress with elevated liver enzymes (ALT, AST) -- moderate severity, dose- and duration-dependent HDL cholesterol suppression (significant, often 30-50% reduction) LDL cholesterol elevation Suppression of endogenous testosterone production via HPG axis negative feedback Mild gastrointestinal discomfort or nausea Back pumps (lower back tightness during exercise, common with 17-alpha-alkylated compounds) Oily skin and mild acne Decreased appetite in some users

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →